The clinical characteristics of the patients are summarised in table 1. In severity of diseases and age between the two groups. There were 20 adenomyoses, 5 adenomyomata and 10 endometriotic ovarian cysts Group) and convention dosing (control group). 70 patients were randomlyĭivided into 2 groups: extended-interval dosing (experimental These patients were told to use barrierĬontraception during the treatment. All patients, 19–40 years of age, with regular 26- to 32-day menstrualĬycles, were recruited from January 2005 to June 2007, having different degrees of dysmenorrhoea, but no hormone use in the 6 Revised American Fertility Society classification (1985). The severity of endometriosis was scored according to the Patients) receiving post-operative adjuvant therapy with triptorelin. The study also included 30 women with an operative and pathologic diagnosis ofĪdenomyomata (10 patients) or endometriotic ovarian cyst (20 Myometrium and (3) increasing serum CA125. Pelvic examination and ultrasound examination or MRI in the Increasing dysmenorrhea (2) firm enlarged uterus detected by The clinicalĭiagnosis of adenomyosis was based on the following criteria: (1) Patients with adenomyosis and endometriosis, using aįorty women with newly diagnosed adenomyosis that required drug treatment were enrolled to this study. The present study was thus designed toĭetermine the effects of triptorelin in the treatment of Clinical characteristics of patientsĭosing regimen. The First Municipal Hospital Affiliated to Guangzhou Medical College Triptorelin depot can be given in an extended-interval Level of luteinizing hormone (LH) starts to normalize inĨ weeks and the 17--oestradiol (E2) level starts to normalize in weeks 7 and 8. That after a single dose of triptorelin depot, the suppression of secretion of follicle-stimulating hormone (FSH) is Administration of GnRH-a by depot every 4 weeks is a well-established regimen worldwide. Pelvic endometriosis as the primary medical therapy orĪs adjuvant therapy to surgical treatment. Is commonly used in the treatment of adenomyosis and Gonadotropin-releasing hormone agonist (GnRH-a) The new regimen reduces the cost of treatment. Conclusion: The use of theĮxtended-interval dosing regimen of triptorelin depot in patients with adenomyosis or endometriosis results in a consistent hypo-oestrogenised state, which is similar to thatĪchieved by the conventional regimen. The hormone profile of the experimental group was similar to that Levels were reduced to the postmenopausal level. And the levels of LH,įSH and E2 were decreased significantly (p ! 0. The uterine volume was reduced 37.6% and 39.2%, respectively. Results: The reliving rate of dysmenorrhea was 100% in patients treated with both the new regimen and the convention regimen after 6 months. Hormone (LH), and follicle-stimulating hormone (FSH). The main outcome measures were relief and recurrence of dysmenorrheaĪnd related climacteric symptoms, reduction of uterine volume, and serum levels of 17--oestradiol (E2), luteinizing In the control group received a conventional regimen (1 injection every 4 weeks for a total of 6 doses). Methods: Patients in the experimental group received a 4-dose regimen (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses). Seventy women suffering from adenomyosis and endometriosis were randomly divided into 2 groups: extended-intervalĭosing (experimental group) and conventional dosing (control group). Methods: This was a prospective observational study in the setting of a hospital outpatient clinic. Regimen in the treatment of patients with adenomyosis andĮndometriosis. Hormone agonist (GnRH-a) and an extended-interval dosing Jia-li Kang Xiao-xia Wang Miao-ling Nie Xiao-hui Huangĭepartment of Obstetrics and Gynecology, First Municipal Hospital Affiliated to Guangzhou Medical College,Īdenomyosis ⴢ Endometriosis ⴢ Gonadotropin-releasingĪims: To determine the effects of gonadotropin-releasing Regimen in the Treatment of Patients with Efficacy of Gonadotropin-Releasing Hormone
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |